These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 37152370)
1. A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors. Shen J; Wei Z; Lv L; He J; Du S; Wang F; Wang Y; Ni L; Zhang X; Pan F Mediators Inflamm; 2023; 2023():7992140. PubMed ID: 37152370 [TBL] [Abstract][Full Text] [Related]
2. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma. Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X Front Oncol; 2023; 13():1182434. PubMed ID: 37346073 [TBL] [Abstract][Full Text] [Related]
3. A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular Carcinoma. Zhu J; Kuang J; Yang Y; Zhang L; Leng B; She R; Zou L Mediators Inflamm; 2023; 2023():6645476. PubMed ID: 37114236 [TBL] [Abstract][Full Text] [Related]
4. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma. Wang L; Wang Q; Li Y; Qi X; Fan X J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643 [TBL] [Abstract][Full Text] [Related]
5. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment. Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528 [TBL] [Abstract][Full Text] [Related]
6. Prognostic prediction and multidimensional dissections of a macrophages M0-related gene signature in liver cancer. Xu X; Wang J Front Endocrinol (Lausanne); 2023; 14():1153562. PubMed ID: 37033261 [TBL] [Abstract][Full Text] [Related]
7. Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma. Pan Y; Zhu Q; Hong T; Cheng J; Tang X Aging (Albany NY); 2024 May; 16(10):9047-9071. PubMed ID: 38787389 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of N Zhu HX; Lu WJ; Zhu WP; Yu S J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346 [TBL] [Abstract][Full Text] [Related]
9. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. Yan C; Niu Y; Ma L; Tian L; Ma J J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876 [TBL] [Abstract][Full Text] [Related]
10. A novel basement membrane-related gene signature predicts prognosis and immunotherapy response in hepatocellular carcinoma. Li B; Che Y; Zhu P; Xu Y; Yu H; Li D; Ding X Front Oncol; 2024; 14():1388016. PubMed ID: 39070142 [TBL] [Abstract][Full Text] [Related]
11. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma. Zhang Q; Zhu B; Yang H; Li F; Qu Y; Lu L; Zhang Q J Gene Med; 2024 Mar; 26(3):e3680. PubMed ID: 38448368 [TBL] [Abstract][Full Text] [Related]
12. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma. Ding D; Wang D; Qin Y Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299 [TBL] [Abstract][Full Text] [Related]
13. Identification of a basement membrane-related genes signature to predict prognosis, immune landscape and guide therapy in gastric cancer. Liu ZY; Xin L Medicine (Baltimore); 2023 Sep; 102(39):e35027. PubMed ID: 37773804 [TBL] [Abstract][Full Text] [Related]
14. Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma. Feng R; Cheng D; Chen X; Yang L; Wu H Biochem Biophys Res Commun; 2024 Jan; 692():149325. PubMed ID: 38056161 [TBL] [Abstract][Full Text] [Related]
15. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development. Liu Z; Zhao P J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083 [TBL] [Abstract][Full Text] [Related]
16. Construction and Validation of Two Hepatocellular Carcinoma-Progression Prognostic Scores Based on Gene Set Variation Analysis. He Q; Fan B; Du P; Jin Y Front Cell Dev Biol; 2022; 10():806989. PubMed ID: 35356272 [No Abstract] [Full Text] [Related]
17. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq. Zhang Z; Li Y; Quan Z; Li Y; Zhu L; Sun S; Chen X Front Immunol; 2024; 15():1397541. PubMed ID: 38774870 [TBL] [Abstract][Full Text] [Related]
18. Integrated Single-cell and Transcriptome Sequencing Analyses Identified PREX1 as an Immune-related Prognostic Biomarker for Liver Hepatocellular Carcinoma. Yang J; Fan LY; Shi KY Int J Med Sci; 2024; 21(8):1559-1574. PubMed ID: 38903921 [No Abstract] [Full Text] [Related]
19. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma. Tao H; Wang C; Lu C; Ma N; Zhu Y; Xuan S; Zhou X Genet Res (Camb); 2022; 2022():7236823. PubMed ID: 35919033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]